Beckman Coulter, Inc. (BEC) - Product Pipeline Analysis by GlobalData

VIEWS: 107 PAGES: 54

More Info
									                                Beckman Coulter, Inc. (BEC) - Product Pipeline Analysis

     Reference Code: GDMEPH3PD                                                                                                  Publication Date: MAY 2011



     Company Snapshot                                                             Company Overview
     Key Information
                                                                                  Beckman Coulter, Inc. (Beckman) is principally engaged in the
     Beckman Coulter, Inc., Key Facts                                             manufacture and marketing of biomedical laboratory instruments,
                                                                                  software and supplies that simplify, automate and innovate complex
     Web Address                            www.beckmancoulter.com
                                                                                  biomedical tests. Its products are used in a wide range of applications
     Turnover            (in       USD 3,663.40                                   such as medical research, clinical trials and drug discovery, and
     Million)                                                                     diagnostic laboratories in hospitals. The company operates through two
                                                                                  reportable business segments, namely, Clinical Diagnostics and Life
     Number of Employees                    11,900                                Science. The company has its operations in the US, Canada, Europe and
     Industry                               Pharmaceuticals and Healthcare        Asia. Its products are sold in over 160 countries worldwide.
     Source:Primary / Secondary Research
     GlobalData



     Beckman Coulter, Inc. Pipeline Products

      Beckman Coulter, Inc. Key Pipeline Products by                              Beckman Coulter, Inc. Key Pipeline Products by Therapy Area
      Equipment Type
     Equipment Type                              No of Products                   Therapy Area                                            No of Products
     Immuno Chemistry                                       23                    Cytomegalovirus infection                                           5
     Infectious Immunology                                   9                    Heparin-induced thrombocytopenia                                      4
     Haematology                                                              7   Pre-eclampsia                                                         4
     Clinical Chemistry                                                       2   Benign prostatic hyperplasia                                          2
     Hospital Information Systems                                             1   Heart attack                                                          2
     Histology And Cytology                                                   1   Sexually transmitted diseases                                         2
                                                                                  Thrombophilia                                                         2
     Source: Primary / Secondary Research                                         Source: Primary / Secondary Research
     GlobalData                                                                   GlobalData


     Beckman Coulter, Inc. Key Pipeline Products by Equipment Type




     Source: Primary / Secondary Research
     GlobalData




     Beckman Coulter, Inc. Key Pipeline Products by                               Beckman Coulter, Inc. Key Pipeline Products by Trial Phase
     Development Stage
     Developmental Stage                        No of Products                    Trial Phase                                             No of Products
     Clinicals                                             26                     Phase IV                                            -
     Pre-Clinicals                                                                Phase III                                           -
                                                 -
     Early development                                                       13   Phase II                                            -
     In Approval Process                                                      4   Phase I                                             -
     Source: Primary / Secondary Research                                         Source: Primary / Secondary Research
     GlobalData                                                                   GlobalData
     Note : (-) indicates 'Not Available'                                         Note : (-) indicates 'Not Available'




Beckman Coulter, Inc. (BEC) - Product Pipeline Analysis                                                                              Reference Code: GDMEPH3PD

Source : www.globalcompanyintelligence.com                                                                                                                   Page 1
     Table of Contents
     Table of Contents................................................................................................................................................................................................................................................................... 2
     List of Tables .......................................................................................................................................................................................................................................................................... 5
     List of Figures......................................................................................................................................................................................................................................................................... 7
     Beckman Coulter, Inc. - Business Description ....................................................................................................................................................................................................................... 8
     Key Facts ............................................................................................................................................................................................................................................................................... 8
     Beckman Coulter, Inc. - Major Products and Services........................................................................................................................................................................................................... 9
           Beckman Coulter, Inc. Pipeline Products by Equipment Type ...................................................................................................................................................................................... 12
           Beckman Coulter, Inc. Pipeline Products by Development Stage................................................................................................................................................................................. 15
           Beckman Coulter, Inc. Pipeline Products by Therapy Area........................................................................................................................................................................................... 17
           Access 25 OH Vitamin D Assay .................................................................................................................................................................................................................................... 19
                 Product Status......................................................................................................................................................................................................................................................... 19
                 Product Description ................................................................................................................................................................................................................................................. 19
           Access ANA Screen Test .............................................................................................................................................................................................................................................. 19
                 Product Status......................................................................................................................................................................................................................................................... 19
                 Product Description ................................................................................................................................................................................................................................................. 19
           Access BPHA Assay...................................................................................................................................................................................................................................................... 19
                 Product Status......................................................................................................................................................................................................................................................... 19
                 Product Description ................................................................................................................................................................................................................................................. 20
                 Product Patent Details ............................................................................................................................................................................................................................................ 20
           Access CMV IgM Assay ................................................................................................................................................................................................................................................ 21
                 Product Status......................................................................................................................................................................................................................................................... 21
                 Product Description ................................................................................................................................................................................................................................................. 21
           Access PlGF Assay ....................................................................................................................................................................................................................................................... 21
                 Product Status......................................................................................................................................................................................................................................................... 21
                 Product Description ................................................................................................................................................................................................................................................. 21
           Access Rubella IgM Assay ............................................................................................................................................................................................................................................ 21
                 Product Status......................................................................................................................................................................................................................................................... 21
                 Product Description ................................................................................................................................................................................................................................................. 22
           ACL AcuStar-HIT IgG Assay ......................................................................................................................................................................................................................................... 22
                 Product Status......................................................................................................................................................................................................................................................... 22
                 Product Description ................................................................................................................................................................................................................................................. 22
           ACL AcuStar-HIT Total Assay ....................................................................................................................................................................................................................................... 22
                 Product Status......................................................................................................................................................................................................................................................... 22
                 Product Description ................................................................................................................................................................................................................................................. 22
           ACL TOP 500 CTS Global Protein C Pathway Test ...................................................................................................................................................................................................... 23
                 Product Status......................................................................................................................................................................................................................................................... 23
                 Product Description ................................................................................................................................................................................................................................................. 23
           ACL TOP 500 CTS-HIT Test ......................................................................................................................................................................................................................................... 23
                 Product Status......................................................................................................................................................................................................................................................... 23
                 Product Description ................................................................................................................................................................................................................................................. 23
           ACL TOP 700- Global Protein C Pathway Test ............................................................................................................................................................................................................. 23
                 Product Status......................................................................................................................................................................................................................................................... 23
                 Product Description ................................................................................................................................................................................................................................................. 24
           ACL TOP 700-HIT Test ................................................................................................................................................................................................................................................. 24
                 Product Status......................................................................................................................................................................................................................................................... 24
                 Product Description ................................................................................................................................................................................................................................................. 24
           AU480 Clinical System-HbA1c Assay ........................................................................................................................................................................................................................... 24
                 Product Status......................................................................................................................................................................................................................................................... 24
                 Product Description ................................................................................................................................................................................................................................................. 24
                 Product Patent Details ............................................................................................................................................................................................................................................ 25
           AU5840 Clinical Chemistry System ............................................................................................................................................................................................................................... 26
                 Product Status......................................................................................................................................................................................................................................................... 26
                 Product Description ................................................................................................................................................................................................................................................. 26
           Chlamydia Test.............................................................................................................................................................................................................................................................. 26
                 Product Status......................................................................................................................................................................................................................................................... 26
                 Product Description ................................................................................................................................................................................................................................................. 26
                 Product Institution Details ....................................................................................................................................................................................................................................... 27
           DxLab Workflow Manager ............................................................................................................................................................................................................................................. 27
                 Product Status......................................................................................................................................................................................................................................................... 27
                 Product Description ................................................................................................................................................................................................................................................. 27

Beckman Coulter, Inc. (BEC) - Product Pipeline Analysis                                                                                                                                                                                                 Reference Code: GDMEPH3PD

Source : www.globalcompanyintelligence.com                                                                                                                                                                                                                                                     Page 2
        HCV Viral Load Test - UniCel DxN ................................................................................................................................................................................................................................ 27
              Product Status......................................................................................................................................................................................................................................................... 27
              Product Description ................................................................................................................................................................................................................................................. 27
        Navios............................................................................................................................................................................................................................................................................ 28
              Product Status......................................................................................................................................................................................................................................................... 28
              Product Description ................................................................................................................................................................................................................................................. 28
              Product Patent Details ............................................................................................................................................................................................................................................ 28
        Neisseria Test................................................................................................................................................................................................................................................................ 29
              Product Status......................................................................................................................................................................................................................................................... 29
              Product Description ................................................................................................................................................................................................................................................. 29
              Product Milestone ................................................................................................................................................................................................................................................... 29
              Product Institution Details ....................................................................................................................................................................................................................................... 29
        p2PSA Prostate Test ..................................................................................................................................................................................................................................................... 30
              Product Status......................................................................................................................................................................................................................................................... 30
              Product Description ................................................................................................................................................................................................................................................. 30
              Product Patent Details ............................................................................................................................................................................................................................................ 30
        sVEGF-R1 Assay........................................................................................................................................................................................................................................................... 34
              Product Status......................................................................................................................................................................................................................................................... 34
              Product Description ................................................................................................................................................................................................................................................. 34
        Synchron Access PIGF Assay....................................................................................................................................................................................................................................... 34
              Product Status......................................................................................................................................................................................................................................................... 34
              Product Description ................................................................................................................................................................................................................................................. 35
        Synchron Access sVEGF R1 Assay .............................................................................................................................................................................................................................. 35
              Product Status......................................................................................................................................................................................................................................................... 35
              Product Description ................................................................................................................................................................................................................................................. 35
        Synchron Access Vitamin D Assay................................................................................................................................................................................................................................ 35
              Product Status......................................................................................................................................................................................................................................................... 35
              Product Description ................................................................................................................................................................................................................................................. 35
        SYNCHRON LX i 725-Anti-TPO Assay ......................................................................................................................................................................................................................... 36
              Product Status......................................................................................................................................................................................................................................................... 36
              Product Description ................................................................................................................................................................................................................................................. 36
        SYNCHRON LXi 725 Anti-Cardiolipin Assay................................................................................................................................................................................................................. 36
              Product Status......................................................................................................................................................................................................................................................... 36
              Product Description ................................................................................................................................................................................................................................................. 36
        SYNCHRON LXi 725 Anti-dsDNA Assay ...................................................................................................................................................................................................................... 36
              Product Status......................................................................................................................................................................................................................................................... 36
              Product Description ................................................................................................................................................................................................................................................. 37
        SYNCHRON LXi 725 CMV IgG Assay .......................................................................................................................................................................................................................... 37
              Product Status......................................................................................................................................................................................................................................................... 37
              Product Description ................................................................................................................................................................................................................................................. 37
        SYNCHRON LXi 725 CMV IgM Assay .......................................................................................................................................................................................................................... 37
              Product Status......................................................................................................................................................................................................................................................... 37
              Product Description ................................................................................................................................................................................................................................................. 37
        SYNCHRON Lxi 725 D-Dimer Assay ............................................................................................................................................................................................................................ 38
              Product Status......................................................................................................................................................................................................................................................... 38
              Product Description ................................................................................................................................................................................................................................................. 38
        SYNCHRON LXi 725 IL-6 Assay ................................................................................................................................................................................................................................... 38
              Product Status......................................................................................................................................................................................................................................................... 38
              Product Description ................................................................................................................................................................................................................................................. 38
        SYNCHRON LXi 725 Intact PTH Assay ........................................................................................................................................................................................................................ 38
              Product Status......................................................................................................................................................................................................................................................... 38
              Product Description ................................................................................................................................................................................................................................................. 39
        SYNCHRON LXi 725 Ischemia Modified Albumin Assay .............................................................................................................................................................................................. 39
              Product Status......................................................................................................................................................................................................................................................... 39
              Product Description ................................................................................................................................................................................................................................................. 39
        Troponin Test - Access Instrument................................................................................................................................................................................................................................ 39
              Product Status......................................................................................................................................................................................................................................................... 39
              Product Description ................................................................................................................................................................................................................................................. 40
        Troponin Test - DxI Instrument ..................................................................................................................................................................................................
								
To top